Recent Articles By The Author
Financials and energy ETFs aren't faring well in the current environment, but there still is a way to make money on them.
Stemline Therapeutics and Flexion Therapeutics both saw their shares climb on positive news developments.
They're the most important executive at most small developmental or early commercialization concerns.
Striking out is painful, but is not as impactful as missing out on the next potential home run because you're still brooding about whiffing on your last investment.
The trio to keep an eye on are U.S.-China trade talks, business investment and political rhetoric.
Jounce Therapeutics and Ocular Therapeutix each provided investors with positive news morsels last week.